DrugPatentWatch Database Preview

Abbvie Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?

ABBVIE INC has eight approved drugs.

There are thirty-seven US patents protecting ABBVIE INC drugs.

There are seven hundred and thirty patent family members on ABBVIE INC drugs in sixty-three countries and fifty-six supplementary protection certificates in thirteen countries.

Summary for Abbvie Inc

International Patents:	730
US Patents:	37
Tradenames:	8
Ingredients:	8
NDAs:	8
Drug Master File Entries:	17
Patent Litigation for Abbvie Inc:	See patent lawsuits for Abbvie Inc

Drugs and US Patents for Abbvie Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		RX	Yes	Yes	8,691,938		Y	Y
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		RX	Yes	Yes	9,006,387
Abbvie Inc	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir	TABLET, TABLET;ORAL	206619-001	Dec 19, 2014		RX	Yes	Yes	8,691,938		Y	Y
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		RX	Yes	Yes	8,686,026		Y

Expired US Patents for Abbvie Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-003	Sep 4, 2001	7,041,319
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-003	Sep 4, 2001	6,074,670
Abbvie Inc	TRICOR	fenofibrate	TABLET;ORAL	021203-003	Sep 4, 2001	4,895,726
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,703,403*PED

Paragraph IV (Patent) Challenges for ABBVIE INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	48 mg		2008-07-01
	Tablets	100 mg		2010-12-21
	Tablets	145 mg		2007-10-19
	Capsules	100 mg		2012-10-31

Non-Orange Book US Patents for Abbvie Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,921,514	Anti-viral compounds
9,394,279	Anti-viral compounds
8,193,367	Polymorph of a pharmaceutical
7,659,405	Polymorph of a pharmaceutical

International Patents for Abbvie Inc Drugs

Country	Document Number	Estimated Expiration
Japan	2013056886
Eurasian Patent Organization	024100
Germany	202012012956
Lithuania	PA2017033

Supplementary Protection Certificates for Abbvie Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
668	Luxembourg		PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
2368890/01	Switzerland		PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
2340029/01	Switzerland		PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
667	Luxembourg		PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Abbvie
• Abbvie Endocrine
• Abbvie Endocrine Inc
• Abbvie Inc